Keyphrases
B Cells
100%
Anti-melanoma
100%
Checkpoint Blockade
100%
Tumor
29%
Toll-like Receptor 7 (TLR7)
29%
CD8+ T Cells
23%
CD40
23%
C57BL
17%
Therapeutic Efficacy
11%
Anti-PD-L1 Antibody
11%
Anti-PD-1
11%
PD-1 Blockade
11%
Knock-in Mouse Model
5%
Transcriptomic Data
5%
Treatment Efficacy
5%
Overall Survival
5%
Combination Therapy
5%
Melanoma
5%
Wild Mice
5%
Tumor-specific
5%
Tumor Immunity
5%
Monotherapy
5%
Immune Cells
5%
Disease Control
5%
B16 Melanoma
5%
Microarray Analysis
5%
Response Control
5%
Tumor Microenvironment
5%
Melanoma Treatment
5%
Melanoma Patients
5%
WT Mice
5%
Complete Tumor Regression
5%
Transcriptome Analysis
5%
Antibody Therapy
5%
CD8+ T Cell Immunity
5%
CTLA-4 Inhibitors
5%
Immune Disease
5%
CXCL13
5%
Antibody Activity
5%
Chemokine CXCL13
5%
Anti-CD19
5%
TCGA Database
5%
Checkpoint Blockade Therapy
5%
Immune Checkpoint
5%
Melanoma Mouse Model
5%
Durable Immune Response
5%
Immunology and Microbiology
B Cell
100%
Programmed Death-Ligand 1
35%
Cytotoxic T-Cell
29%
Agonist
17%
Immunotherapy
17%
C57BL 6 Mouse
17%
Wild Type Mouse
11%
Immunocompetent Cell
5%
Immunity
5%
Mouse Model
5%
Immune Response
5%
Transcriptome
5%
Gene Expression Assay
5%
CD19
5%
Overall Survival
5%
Adoptive Immunity
5%
Knockout Mouse
5%
Tumor Immunity
5%
Cytotoxic T Lymphocyte Antigen 4 Antibody
5%
CXCL13 Chemokine
5%
CXCL13
5%